FI89454B - Foerfarande foer framstaellning av ett lyofiliserat antibakteriellt preparat - Google Patents

Foerfarande foer framstaellning av ett lyofiliserat antibakteriellt preparat Download PDF

Info

Publication number
FI89454B
FI89454B FI880027A FI880027A FI89454B FI 89454 B FI89454 B FI 89454B FI 880027 A FI880027 A FI 880027A FI 880027 A FI880027 A FI 880027A FI 89454 B FI89454 B FI 89454B
Authority
FI
Finland
Prior art keywords
aspoxicillin
preparation
lyophilized
salt
antibacterial
Prior art date
Application number
FI880027A
Other languages
English (en)
Finnish (fi)
Other versions
FI880027A (fi
FI880027A0 (fi
FI89454C (sv
Inventor
Keiichi Kohno
Hiroshi Miura
Yoshiyuki Hirakawa
Toshiyuki Ueki
Seiichi Morikuni
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of FI880027A0 publication Critical patent/FI880027A0/fi
Publication of FI880027A publication Critical patent/FI880027A/fi
Publication of FI89454B publication Critical patent/FI89454B/fi
Application granted granted Critical
Publication of FI89454C publication Critical patent/FI89454C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (3)

1. Förfarande för framstäilning av lyofiliserad antibakterie-produkt, som innehaller som aktiv komponent aspoxici11 in, kännetecknat därav, att aspoxicillin och alkali-salt av aspoxicillin i mol förhäl1andet 1 : 0,7-7 och vid behov aikaiimetal1 haiogenid löses i destillerat injiseringsvatten och lösningen 1yofi1iseras.
2. Förfarande enligt patentkravet 1, kännetecknat därav, att aspoxici11inet är aspoxici11in-anhydrid eller aspoxici11in-trihydrat, och aikaiimetallhalogeniden är nat-riumklorid.
3. Förfarande enligt patentkravet 1, kännetecknat därav, att i stället för aspoxici11inets alkalimetallsalt används aikaiimetallhydroxid, alkalimetallkarbonat eller alkalimetal1vätekarbonat ca 0,4 - 0,88 mol per mol aspoxicil-1 in.
FI880027A 1987-01-14 1988-01-06 Förfarande för framställning av ett lyofiliserat antibakteriellt prepa rat FI89454C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP62006868A JPS63174927A (ja) 1987-01-14 1987-01-14 抗菌性凍結乾燥製剤
JP686887 1987-01-14

Publications (4)

Publication Number Publication Date
FI880027A0 FI880027A0 (fi) 1988-01-06
FI880027A FI880027A (fi) 1988-07-15
FI89454B true FI89454B (fi) 1993-06-30
FI89454C FI89454C (sv) 1993-10-11

Family

ID=11650214

Family Applications (1)

Application Number Title Priority Date Filing Date
FI880027A FI89454C (sv) 1987-01-14 1988-01-06 Förfarande för framställning av ett lyofiliserat antibakteriellt prepa rat

Country Status (18)

Country Link
US (1) US4966899A (sv)
EP (1) EP0278243B1 (sv)
JP (1) JPS63174927A (sv)
KR (1) KR930001830B1 (sv)
CN (1) CN1024754C (sv)
AT (1) ATE61222T1 (sv)
AU (1) AU597463B2 (sv)
CA (1) CA1308358C (sv)
DE (1) DE3861866D1 (sv)
DK (1) DK15088A (sv)
ES (1) ES2031930T3 (sv)
FI (1) FI89454C (sv)
GR (1) GR3001565T3 (sv)
HK (1) HK63592A (sv)
HU (1) HU197985B (sv)
IE (1) IE60049B1 (sv)
IL (1) IL85031A (sv)
SG (1) SG60292G (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367090B1 (en) * 1988-11-01 1994-01-12 Schwarz Pharma Ag Lyophilized MDM composition and method of making it
AU700545B2 (en) * 1994-05-02 1999-01-07 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
US8252228B1 (en) * 2008-10-13 2012-08-28 Abbott Cardiovascular Systems Inc. Methods for sterilizing carriers for treatment of a kidney
CN102372727A (zh) * 2010-08-10 2012-03-14 海南美好西林生物制药有限公司 一种阿扑西林钠的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733404A (en) * 1970-09-04 1973-05-15 Squibb & Sons Inc Antibacterial composition containing alpha-aminobenzyl penicillins
US4053609A (en) * 1975-09-12 1977-10-11 Tanabe Seiyaku Co., Ltd. Penicillins and processes for preparing the same
DE2623835C2 (de) * 1976-05-28 1978-03-02 C.H. Boehringer Sohn, 6507 Ingelheim Verfahren zur Herstellung von Natriumampicillin
GB1539510A (en) * 1976-08-23 1979-01-31 Beecham Group Ltd Injectable compositions
JPS5640686A (en) * 1979-09-11 1981-04-16 Tanabe Seiyaku Co Ltd Purification of penicillin derivative
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof

Also Published As

Publication number Publication date
ES2031930T3 (es) 1993-01-01
US4966899A (en) 1990-10-30
EP0278243A1 (en) 1988-08-17
SG60292G (en) 1992-09-04
HU197985B (en) 1989-07-28
IL85031A (en) 1992-07-15
EP0278243B1 (en) 1991-03-06
CN1034131A (zh) 1989-07-26
CA1308358C (en) 1992-10-06
KR930001830B1 (ko) 1993-03-15
ATE61222T1 (de) 1991-03-15
HUT46212A (en) 1988-10-28
JPS63174927A (ja) 1988-07-19
DE3861866D1 (de) 1991-04-11
IE60049B1 (en) 1994-05-18
DK15088A (da) 1988-07-15
AU597463B2 (en) 1990-05-31
FI880027A (fi) 1988-07-15
DK15088D0 (da) 1988-01-13
IE880049L (en) 1988-07-14
JPH053847B2 (sv) 1993-01-18
AU1022688A (en) 1988-07-21
FI880027A0 (fi) 1988-01-06
CN1024754C (zh) 1994-06-01
FI89454C (sv) 1993-10-11
GR3001565T3 (en) 1992-11-23
HK63592A (en) 1992-08-28
KR880008812A (ko) 1988-09-13

Similar Documents

Publication Publication Date Title
KR840001776B1 (ko) 세프타지딤 펜타하이드레이트의 제조방법
US5589491A (en) Injection and injection kit containing omeprazole and its analogs
ES2298295T3 (es) Preparacion liofilizada de pantoprazol e inyeccion de pantoprazol.
EP0216459B1 (en) 9-substituted guanine monohydrates
BG63821B1 (bg) Фармацевтичен състав на стабилизиран карбапенемовантибиотик и метод за получаване
CA1056729A (en) Injectable amoxycillin composition
WO2009051626A1 (en) Cephalosporin derivative formulation
FI89454B (fi) Foerfarande foer framstaellning av ett lyofiliserat antibakteriellt preparat
FI83476C (sv) Förfarande för framställning av en beredning av 7 -difluorometyltioac etamido-7 -metoxi-3-/1-(2-hydroxialkyl)-1H-tetrazol-5-yl/tiometyl-1-d etia-1-oxa-3-cefem-4-karboxisyra
KR880001154B1 (ko) 항생물질의 안정화 방법
JP2958567B2 (ja) 非経口用凍結乾燥ｂｍｙ―２８１４２ジ塩酸塩
EP1304106A1 (en) FREEZE-DRIED PREPARATION OF N- o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME
ES2258569T3 (es) Produccion de cefalosporina.
MXPA03002770A (es) Infusion de ciprofloxacina con un contenido de acido reducido y estable al almacenamiento.
CA1170571A (en) Pharmaceutical compositions
JP2012501331A (ja) カンフォスファミド製剤及びその製造方法
JP2761005B2 (ja) セファロスポリン含有注射用組成物
CA1275932C (en) Solution containing luprostiol
JPH053848B2 (sv)
GB1592053A (en) Oxytetracycline compositions
PT91383B (pt) Processo para a preparacao do acido (5r,6s)-2-carbamoiloximetil-6-{(1r)-hidroxi-etil}-2-penem-3-carboxilico sob a forma cristalina e de composicoes farmaceuticas que o contem
JPS61130223A (ja) 抗菌性凍結乾燥製剤
GB2072675A (en) Cephapirin salts
EP0381915A1 (en) Process for preparing alkali metal salts of 3,7-substituted 7-aminocephalosporanic acid derivatives.
JP2002542288A (ja) 注射可能な新規抗凝固薬組成物

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: TANABE SEIYAKU CO., . LTD.